Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?

The article explains why osteoporosis patients treated with antiresorptive (AR) drugs are considered like oncology patients regarding their oral health care. It discusses the efficacy of biphosphonates and denosumab in treating osteoporosis. It refers to AR-related osteonecrosis of the jaw (ARONJ) as a complication in AR-treated patients and cites the lack knowledge about differential risks associated with the development of ARONJ between osteoporosis and cancer exposed to oral treatments.